Tjalma W, De Cuyper E, Weyler J, Van Marck E, De Pooter C, Albertyn G, van Dam P
Laboratory of Cancer Research and Clinical Oncology, Antwerp University, Belgium.
Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113-7. doi: 10.1016/s0002-9378(98)70636-2.
The oncoprotein bcl-2 inhibits apoptosis. The purpose of this study was to assess the expression of bcl-2 in human cervical carcinoma and to correlate this with clinicopathologic parameters.
Immunohistochemical staining for bcl-2 protein (MoAB clone 124) was performed on operative tissue specimens from 22 patients with carcinoma in situ of the cervix and from 137 patients with invasive cervical carcinoma (International Federation of Gynecology and Obstetrics stages I to IV). The immunoreactivity of bcl-2 was scored as positive (> or = 5% staining cells) or negative (< 5% staining cells).
Eighty-two percent of in situ carcinomas and 61% of invasive cervical carcinomas were bcl-2 positive. Expression of bcl-2 was correlated to tumor stage (p < 0.001) and to presence of vascular (p < 0.005) or lymphatic tumor (p < 0.023) permeation. In univariate analysis there was a strong relationship between bcl-2 expression and overall survival (p < 0.001). In multivariate analysis bcl-2 expression (p < 0.001), International Federation of Gynecology and Obstetrics stage (p = 0.011), and presence of lymphatic permeation (p = 0.014) proved to be independent prognostic factors.
Expression of bcl-2 is lost during tumor progression and is a strong prognostic parameter, suggesting that the regulation of apoptosis plays an important role in the behavior of cervical carcinomas. Better understanding of the mechanisms involved may lead to improved medical treatment strategies.
癌蛋白bcl - 2可抑制细胞凋亡。本研究旨在评估bcl - 2在人宫颈癌中的表达情况，并将其与临床病理参数进行关联分析。
对22例宫颈原位癌患者和137例浸润性宫颈癌患者（国际妇产科联盟分期为I至IV期）的手术组织标本进行bcl - 2蛋白（单克隆抗体克隆124）的免疫组化染色。bcl - 2的免疫反应性分为阳性（染色细胞≥5%）或阴性（染色细胞<5%）。
82%的原位癌和61%的浸润性宫颈癌bcl - 2呈阳性。bcl - 2的表达与肿瘤分期（p<0.001）以及血管（p<0.005）或淋巴转移（p<0.023）相关。单因素分析显示bcl - 2表达与总生存率之间存在密切关系（p<0.001）。多因素分析表明，bcl - 2表达（p<0.001）、国际妇产科联盟分期（p = 0.011）和淋巴转移情况（p = 0.014）是独立的预后因素。
bcl - 2的表达在肿瘤进展过程中降低，是一个重要的预后参数，提示细胞凋亡的调控在宫颈癌的发生发展中起重要作用。深入了解其中的机制可能有助于改进医疗治疗策略。
